Plain Language Summaries

Standalone, citable summaries published in the Future Science Group journals written to be understood by a lay audience

Inflammatory and Immune-related disorders

Plain language summary of the VOLTAIRE-CD study in people with moderate-to-severe active Crohn’s disease

This plain language summary from Immunotherapy describes the VOLTAIRE-CD study, in which researchers compared BI 695501, a biosimilar to treat Crohn’s disease, with the original drug, adalimumab.

Read the full article here.

The original article on which this plain language summary is based is titled ‘Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn’s disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial’ and was published in The Lancet Gastroenterology and Hepatology. Read the original article here.

Plain language summary of the VOLTAIRE-RA study in patients with moderate-to-severe rheumatoid arthritis

The latest plain language summary of publication from Immunotherapy presents results from the VOLTAIRE-RA study looking at how effective and safe the biosimilar drug BI 695501 is in treating people with rheumatoid arthritis.

Read the summary here.

The original article on which this summary is based is called ‘Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study’ and was originally published in the journal Annals of the Rhematic Diseases. The original article can be read here.